Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

• Published in: Journal for immunotherapy of cancer Vol. 6; no. 1; pp. 68 - 10
• Main Authors: Iyer, Priyanka C, Dadu, Ramona, Gule-Monroe, Maria, Busaidy, Naifa L, Ferrarotto, Renata, Habra, Mouhammed Amir, Zafereo, Mark, Williams, Michelle D, Gunn, G Brandon, Grosu, Horiana, Skinner, Heath D, Sturgis, Erich M, Gross, Neil, Cabanillas, Maria E
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.07.2018; BMJ Publishing Group LTD; BioMed Central; BMJ Publishing Group
• Subjects: Aged; Aged, 80 and over; Anaplastic thyroid cancer; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Cancer; Cancer therapies; Cancer treatment; Carcinoma; Chemotherapy; Dabrafenib; Development and progression; Drug therapy; FDA approval; Female; Genomics; Health aspects; Humans; Immunotherapy; Lenvatinib; Male; Medical research; Metastasis; Middle Aged; Monoclonal antibodies; Mutation; Patients; Protein Kinase Inhibitors - administration & dosage; Radiation; Retrospective Studies; Salvage; Salvage Therapy; Surgery; Targeted cancer therapy; Thyroid cancer; Thyroid Carcinoma, Anaplastic - drug therapy; Thyroid Carcinoma, Anaplastic - metabolism; Thyroid Carcinoma, Anaplastic - pathology; Thyroid Neoplasms - drug therapy; Thyroid Neoplasms - metabolism; Thyroid Neoplasms - pathology; Treatment Outcome; Tumors; Anaplastic thyroid cancer; Salvage; Thyroid cancer; Immunotherapy; Undifferentiated; Dabrafenib; Lenvatinib; Trametinib

Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these tumors acquire resistance to KI and patients succumb to their disease. Salvage therapy in this setting...